Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

<b>Background</b>: The majority of melanoma is diagnosed in individuals between 55 and 84 years old. Current data varied in reporting differences in survival outcomes amongst different age groups. <b>Methods:</b> A retrospective, multi-center, provincial cohort database was u...

Full description

Bibliographic Details
Main Authors: Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng
Format: Article
Language:English
Published: MDPI AG 2023-09-01
Series:Current Oncology
Subjects:
melanoma
immune checkpoint inhibitor
nivolumab
pembrolizumab
ipilimumab plus nivolumab
age
Online Access:https://www.mdpi.com/1718-7729/30/10/646

Similar Items

Similar Items